In order to control and eliminate tuberculosis (TB), the management of latent TB infection (LTBI) as well as active TB is inevitable. Diagnosis and treatment of LTBI is targeted for high risk individuals for developing TB. High risk groups involve recent contacts with infectious TB patients, subjects with immunosuppressed conditions, and health care personnels. Diagnosis of LTBI is done using tuberculin skin test or recently developed ex-vivo interferon-gamma releasing assays after excluding active TB clinically. The main LTBI treatment regimen is 9 months of isoniazid treatment, and additional regimens include rifampicin monotherapy (4 months in adults and 6 months in children) or a combined regimen of isoniazid and rifampicin for 3 months. 

